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Abstract 1 
Background: This study describes the post-diagnosis care-seeking costs incurred by people 2 
living with TB and/or HIV and their households, in order to identify the potential benefits of 3 
integrated care.  4 
Methods: We conducted a cross-sectional study with 454 participants with TB or HIV or both in 5 
public primary health care clinics (PHC clinics) in Ekurhuleni North Sub-District, South Africa. We 6 
collected information on visits to health facilities, direct and indirect costs for participants and 7 
for their guardians and caregivers. We define ‘integration’ as receipt of both TB and HIV services 8 
at the same facility, on the same day. Costs were presented and compared across participants 9 
with TB/HIV, TB-only and HIV-only. Costs exceeding 10% of the participant`s income were 10 
considered catastrophic.  11 
Results: Participants with both TB and HIV faced a greater economic burden (USD $74/month) 12 
than those with TB only (USD $68/month) or HIV only (USD $40/month). On average, people 13 
with TB/HIV made 18.4 visits to health facilities, more than TB-only participants or HIV-only 14 
participants who made 16 and 5.1 visits respectively. However, people with TB/HIV had fewer 15 
standalone TB (10.9) and HIV (2.2) visits than those with TB-only (14.5) or HIV-only (4.4). 16 
Although people with TB/HIV had access to ‘integrated’ services, their time loss was substantially 17 
higher than for other participants.  Overall, 55% of participants encountered catastrophic costs. 18 
Access to official social protection schemes was minimal. 19 
Conclusions: People with TB/HIV in South Africa are at high risk of catastrophic costs. To some 20 
extent, integration of services reduces the number of standalone TB and HIV of visits to the health 21 
facility. It is however unlikely that catastrophic costs can be averted by service integration alone.  22 
Our results point to the need for timely social protection, particularly for HIV-positive people 23 
starting TB treatment.   24 
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MAIN TEXT  1 
Introduction 2 
The launch of the Sustainable Development Goals (SDGs) and Universal Health Coverage reflect 3 
an increased global focus on the interaction between health outcomes and poverty.  Health sector 4 
policy-makers are becoming increasingly interested in interventions and service delivery models 5 
that may best prevent impoverishment. While there has been much investigation into the impact 6 
of service integration on provider costs, much less attention has been focussed on the potential 7 
economic and poverty reduction benefits to service users, particularly vulnerable groups (World 8 
Bank, 2009; World Health Organization et al., 2009; Atun et al., 2010).   9 
Household and patient-incurred costs associated with health shocks have long been recognized 10 
as key contributors to impoverishment (Heltberg and Lund, 2009; Alam and Mahal, 2014; 11 
Wagstaff and Lindelow, 2014).  In the case of tuberculosis (TB), patient-incurred costs are a major 12 
barrier to access to health services in low-income countries (Ensor and Cooper, 2004; O’Donnell 13 
et al., 2007), and have been associated with negative TB treatment outcomes (Wingfield et al., 14 
2014). Even where TB services are offered free of charge, the high costs of access such as 15 
transportation and opportunity cost of time spent accessing care may provide obstacles for 16 
vulnerable groups, while worsening or creating poverty in those that proceed to seek care (Xu et 17 
al., 2007).  When faced with high costs of accessing TB care and a reduced ability to earn income 18 
due to illness, some TB patients resort to selling off their assets and taking interest-bearing loans 19 
(Lönnroth et al., 2014). This can result in a long term poverty impact for both patients and their 20 
households (Xu et al., 2003; Gottret and Schieber, 2006; WHO, 2010; Lönnroth et al., 2014).  21 
For people accessing care for both TB and HIV, health service integration has the potential to 22 
reduce this economic burden.  Integration may benefit patients by enabling health improvements 23 
and cost reductions through less fragmented services, improved continuity of care, and better 24 
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retention in care (Sweeney et al., 2012). Integration may also facilitate cost reductions through 1 
fewer visits to facilities and reduced delays in accessing treatment (Legido-Quigley et al., 2013). 2 
In 2012, TB was the primary cause of death for 25% of all HIV-associated deaths in South Africa, 3 
and 61% of all people with TB were HIV-positive (WHO, 2015).  The country has developed 4 
guidelines for the integration of TB and HIV services with preference for a “one stop shop”, where 5 
services are provided under one roof (National Department of Health, 2011). TB/HIV integration 6 
is expected to “ensure comprehensive management of the patient, reduce morbidity and 7 
mortality and improve treatment outcomes” (Chehab et al., 2013; National Department of Health, 8 
2014). Integration however remains poorly implemented in South Africa (Churchyard et al., 9 
2014). Although services are commonly provided ‘under one roof’, they may often not be 10 
provided by a single provider, nor will patients be correctly referred between providers.  As a 11 
result the evidence base on the impact of  TB/HIV integration on patient-relevant outcomes is 12 
small and inconsistent (Kaplan et al., 2014; Jacobson et al., 2015; Ledibane et al., 2015).     13 
To date, TB patient costing studies in South Africa (Chimbindi et al. 2015, Foster et al. 2015)  have 14 
not comprehensively assessed the economic impact of illness on people with both TB and HIV.  15 
The purpose of this paper is to comprehensively describe the post-diagnosis care-seeking 16 
behaviour, patient costs incurred and coping strategies adopted by people living with TB and/or 17 
HIV and their households, in order to identify the potential benefits of integrated care. To present 18 
this, we collected data on the costs incurred by participants in the period immediately following 19 
receipt of a TB and/or HIV diagnosis and including the first 3-5 months of care, as this is the 20 
period when previous studies have shown patients to incur the highest costs (Foster et al. 2015). 21 
We present this evidence in order to support policy makers as they assess the potential benefits 22 
from the improved implementation of TB/HIV integration.  23 
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Methods    1 
Study setting 2 
The study was conducted in Ekurhuleni North; a sub-district in Gauteng province, South Africa. 3 
Ekurhuleni had approximately 3.2 million inhabitants in 2013 (City of Ekurhuleni, 2013) and a 4 
population density of approximately 1609 people per square kilometre (Statistics South Africa, 5 
2015). Ekurhuleni has a high unemployment rates of 28.8% in the general population and 36.9% 6 
among persons between ages of 15 and 35 (City of Ekurhuleni, 2013, 2014). In 2013, 8% of the 7 
people living in Ekurhuleni reported that they did not have any source of income and 27.9% were 8 
considered to be living below a nationally defined minimum living standard   (City of Ekurhuleni, 9 
2013).  The South Africa District Health Barometer of 2013 estimated a TB case notification rate 10 
of 336 per 100 000 for Ekurhuleni (Massyn et al., 2014).  According to a national HIV prevalence, 11 
incidence and behaviour survey, the HIV prevalence for Ekurhuleni  was 14.3% (10.3% - 19.5%) 12 
in 2012 (Simbayi et al., 2014).  13 
Study design and baseline data collection 14 
This was a cross-sectional study nested within a cluster randomised trial – the MERGE trial. The 15 
MERGE trial evaluated the effect of implementing an intervention to optimise/improve TB/HIV 16 
integration on morbidity, mortality and retention in care at public primary health care clinics 17 
(PHC clinics) (Kufa et al., 2014). A total of 18 PHC clinics, the study clinics, were randomly 18 
allocated to the intervention or control arm. To be eligible for inclusion in the trial, the clinics had 19 
to meet the following criteria: no conflicting research study in progress at the clinic, clinic has at 20 
least 40 TB cases per year, and the clinic has available TB data.  21 
Participation in the MERGE trial was not a requirement for inclusion in the patient costs study. 22 
Instead MERGE trial participants had an equal chance of also being enrolled in the patient costs 23 
study if eligible. Cost data were collected using structured questionnaires at the 18 study clinics 24 
between April and October 2013. Participants were selected consecutively and enrolled if they 25 
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met any one of the following criteria:  i) received a TB diagnosis 3-5 months prior to interview 1 
AND had a positive HIV test at any time (“TB/HIV”); ii) received a TB diagnosis 3-5 months prior 2 
to interview and was HIV negative at time of enrolment (“TB-only”) iii) tested HIV positive for the 3 
first time 3-5 months prior to interview and was not on treatment for TB at the time of enrolment 4 
(“HIV-only”). The time period was informed by previous research which showed that participant 5 
recall becomes diminished at around 4 months onwards (Mauch et al., 2011).  All participants 6 
reported a known positive or negative HIV status. Unlike TB, HIV positive reporting was not 7 
confirmed with clinic records. Participant numbers were capped at 50 per site, although only 3 of 8 
18 sites reached this cap due to low participant numbers at the facilities.   9 
Questionnaires 10 
Questionnaires were adapted from the Tool to Estimate Patients’ Costs that was developed by the 11 
Tuberculosis Coalition for Technical Assistance (TBCTA) and the United States Agency for 12 
International Development (USAID) (USAID and World Health Organization, 2008). Separate 13 
questionnaires were developed for people being treated for TB (regardless of HIV status) and for 14 
HIV-positive people not being treated for TB to accommodate different pathways of care. Both 15 
questionnaires captured similar level of detail on the different events in the pathway of care. 16 
Questionnaires focused on the period in the first 3-5 months after participants knowing or being 17 
told they had TB (‘post-diagnosis’) to understand the costs of accessing integrated services. 18 
Demographic characteristics such as gender, age, ethnicity and nationality, levels of education, 19 
marital status, employment at the time of receipt of diagnosis, and the impact of illness on normal 20 
productive patterns were collected. Questionnaires also included detailed questions on the 21 
number of visits made to a range of providers, including the participant’s local PHC clinic (our 22 
study clinic), other public facilities, general practitioners, hospitals, traditional healers and 23 
pharmacies. A distinction was made between integrated visits and stand-alone visits for TB 24 
and/or HIV services at the study clinic.  We define ‘integration’ as physical and temporal 25 
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integration, or receipt of both TB and HIV services at the same facility, on the same day (Mayhew 1 
et al., 2016).   2 
It was not feasible to measure costs for every visit made by participants; questions therefore 3 
elicited estimates of direct costs, time spent and income loss for the most recent visit to each 4 
provider, and the number of visits made to each provider type during the treatment period.  The 5 
questionnaires also captured information about strategies adopted by participants to cope with 6 
costs of illness. Coping strategies enquired of include: taking interest-bearing loans from lenders, 7 
borrowing money from friends or relatives, selling personal goods, and receipt of grants or 8 
charitable donations. 9 
Data analysis  10 
The data were captured in a secure electronic database and exported into Stata 14 and Microsoft 11 
Excel for analysis (Microsoft, 2014; Stata Corp, 2015). An ‘available case analysis’ assumed 12 
unavailable data values were missing at random.  All costs were converted to an average monthly 13 
cost to facilitate comparison across participants who had received diagnosis between 3-5 months 14 
prior to interview.  15 
Direct costs were defined as medical and non-medical expenses paid out-of-pocket (OOP). 16 
Medical expenses included consultation fees and any OOP payment for medicines and diagnostics 17 
paid at any provider. Direct non-medical expenses included the travel costs of participants and 18 
guardians if any, food costs incurred while in hospital, money spent buying any special foods or 19 
dietary supplements due to illness, and any interest incurred on loans taken out to meet the costs 20 
of OOP payments. Direct medical and non-medical costs were determined as the product of the 21 
reported expense for the most recent visit to each provider type and the number of visits made 22 
to that provider during the post-diagnosis period; these were then divided by the number of 23 
months in the post-diagnosis period.  24 
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We use reported income loss as our primary measure of indirect costs for participants.  To 1 
facilitate comparison with other patient cost studies, we also report separately on time the 2 
participants spent seeking care or were unable to work. We estimated the mean time spent per 3 
month using the total time reported for the most recent visit to each provider time, multiplied by 4 
the total monthly visits to each provider.  Indirect costs for guardians and carers were defined as 5 
the opportunity cost of time spent away from their daily productive routine, including travel to 6 
health facilities, consultation time, and covering household chores usually done by the 7 
participant. As guardians and carers were not interviewed directly about their income loss, the 8 
opportunity cost of this time for guardians and carers was estimated using median income of 9 
elementary occupations in South Africa, R 1517 per month (Statistics South Africa, 2010) 10 
multiplied by the mean time loss. Loan costs were calculated as the difference between the 11 
borrowed amount and the amount paid back.  12 
We also estimated catastrophic costs incurred due to TB and/or HIV. Catastrophic costs are 13 
calculated as a proportion of total costs (direct and indirect) to an income (personal or 14 
household).  The principle of catastrophic costs is rooted in identifying when patients and their 15 
households involuntarily reduce expenditure on basic household needs such as food, clothing and 16 
education in order to pay for health care (Ranson, 2002). According the World Health 17 
Organization (WHO) approach, costs are defined as catastrophic when total costs incurred (direct 18 
and indirect combined) exceed a given threshold of household income (World Health 19 
Organization, 2015).  In the absence of reliable data on household income, we adopted a threshold 20 
of 10% of individual participant  income (Barter et al., 2012).  This threshold has been a widely 21 
used benchmark for catastrophic costs in many patient costing studies (Xu et al., 2003; Russell, 22 
2004; Tanimura et al., 2014; Wingfield et al., 2014; Foster et al., 2015), due to the challenges of 23 
measuring household rather than individual income. An alternative 20% threshold of household 24 
income is also being increasingly used in the case of TB, due an observed association between this 25 
level of cost and negative health outcomes in Peru (Wingfield et al. 2014). We varied the 26 
catastrophic cost threshold in our analysis from 5-25% to understand the impact of this arbitrary 27 
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threshold (Russell 2004, Ukwaja, Alobu & Hopewell 2013). To avoid mathematical errors 1 
associated with division by zero, an arbitrary value of USD1 was assigned to income for those 2 
participants  who reported zero income or where income was a missing value (Foster et al., 2015).  3 
We adopted a descriptive cost analysis due to the small sample size of some of the comparison 4 
groups.  Prior to analysis, all costs were converted from the South African rand (ZAR) to the 5 
United States dollar (USD) using the average rate during the period of data collection in 2013; 6 
ZAR 9.62= USD 1 (OANDA, 2016). Despite skewness and non-normality of cost data, arithmetic 7 
means were used in all calculations as was done in previous studies (Wingfield et al. 2014) and 8 
in line with the principles of economic evaluation (Bill and Melinda Gates Foundation et al., 2014). 9 
Standard deviations were used as measures of dispersion for cost data and inter-quartile ranges 10 
for continuous descriptive data.  11 
Ethical considerations 12 
Ethical approval was obtained from the authors institute. The study was also registered in the 13 
clinical trials register for South Africa (registration number DOH-27-10113846) and additional 14 
permission to conduct the study was sought from the Ekurhuleni health department. 15 
Results 16 
We invited 475 participants meeting the inclusion criteria to participate in the study, and 463 17 
consented to participate.  The most common reason for non-inclusion was receipt of diagnosis 18 
outside of the window of 3-5 months prior to interview.  Of the 463 enrolled, 454 participants 19 
from 18 PHC clinics were included in the analysis, with nine participants excluded because data 20 
on their gender were missing at analysis stage. The majority of the participants included in the 21 
analysis had received a diagnosis of HIV only (n = 298; 66% of sample).  Forty TB-only 22 
participants and 116 TB/HIV participants were recruited. Of the TB/HIV participants, 20 received 23 
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both TB and HIV diagnoses on the same day, and an additional 46 received both diagnoses within 1 
two months of each other.  2 
Descriptive characteristics 3 
Characteristics of the study population are presented in Table I. The majority of participants were 4 
unmarried (58%). Most participants were female (64%), and educated above grade 8 (84%). 5 
Participants born in South Africa and those of African origin made up 83% and 97% of the study 6 
population respectively. Unemployment was very high across all participant groups; 45% of 7 
enrolled participants were unemployed at the time of receiving their diagnosis, as compared to a 8 
national unemployment rate of 25% (Statistics South Africa, 2015). Median monthly income was 9 
$128 at the time of diagnosis of TB and/or HIV.  Of those who were employed at the time of 10 
diagnosis, 6% had a monthly income below the national poverty line of $52 per month (Statistics 11 
South Africa, 2014). The highest income at the time of diagnosis was reported by the TB/HIV 12 
group (median $150 per month), while the TB-only group had the lowest average income ($88 13 
per month). 14 
A large proportion of participants had informal carers; 55% of those with TB, 37% of those with 15 
HIV and 48% of those with TB/HIV.  The impact of illness and care-seeking had variable effects 16 
on participants’ and household members’ income-earning activities.  Across all participant 17 
groups, 19% of participants missed work due to illness and 21% of participants were unable to 18 
complete their normal household duties in the post-diagnosis period.  People with TB were more 19 
likely to miss work with the highest proportion being 31% among TB/HIV participants.  20 
Health service use 21 
All study facilities offered integrated care for both TB and HIV as defined in the methods section. 22 
Actual practice at study facilities varied considerably; in some facilities visits were integrated at 23 
the provider level where both services delivered by the same provider or the consultation level 24 
where both services delivered within the same consultation, though the latter was rare. Table II 25 
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shows the overall mean number of clinic visits and by visit type, for each participant group. 1 
TB/HIV participants on average made 5 ‘integrated’ visits in the post-diagnosis period. TB only 2 
participants also received integrated visits when for HIV testing and collecting test results – on 3 
average this was 0.8 visits per person across study facilities.  4 
 In the post-diagnosis period, all participants made relatively few visits to providers outside the 5 
public health system.  The average total number of visits to other facilities and providers ranged 6 
from 0.6 in the TB only group to 0.2 in the HIV only group. The total number of participants 7 
accessing other types of health provider, and mean number of visits by those participants, is 8 
presented in the Appendix, Table II. The largest proportion of participants accessing care from 9 
providers outside the public health system was among the TB/HIV participant group, at 23.28%. 10 
Fifteen percent of TB-only participants and 14% of HIV-only participants reported use of 11 
providers outside the public health system respectively. Thirteen TB/HIV participants were 12 
hospitalized, as compared to 2 HIV-only participants and zero TB-only participants. 13 
All people with TB visited the study health facilities at least 4 times per month in the post-14 
diagnosis period. HIV only participants made the fewest visits to study facilities over the study 15 
period (mean 1 visit per month).  16 
Patient costs 17 
Table III presents patient-incurred costs in the post-diagnosis period. The highest total costs in 18 
the post-diagnosis period were reported by TB/HIV and TB-only participants; $74.07 and $68.33 19 
per month respectively. Costs for the HIV-only group ($40.41 per month) were substantially 20 
lower. Indirect costs contributed the majority of the total costs, at 71% of total cost for TB/HIV 21 
participants, 86% of total cost for TB-only participants, and 55% of total cost for HIV-only 22 
participants. 23 
Direct OOP costs incurred by participants ranged from $9.86 per month for TB-only participants 24 
to $21.72 per month for TB/HIV participants (Table III).  Detailed costs incurred at all facility 25 
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types are listed in the Appendix, Table II.  Direct costs were largely driven by costs of special food 1 
purchased as nutritional supplements for the illnesses in question. Monthly costs of special foods 2 
ranged from $8.06 to $13.40 per month, representing 53% of direct costs for HIV-only 3 
participants, 60% of direct costs for TB/HIV participants, and 82% of direct costs for TB-only 4 
participants. Expenditure on special foods alone represented an average of 30%, 13%, and 27% 5 
of total income for HIV-only, TB-only, and TB/HIV participants respectively. None of the 6 
interviewed participants incurred direct medical costs at the study clinic, or at any other PHC 7 
clinic. Participants who sought care from health facilities outside the public health system, 8 
particularly those with TB/HIV, incurred some direct medical costs; an average of $1.71 per 9 
month was observed for TB/HIV participants The highest direct medical costs from providers 10 
outside the public health system were incurred by participants accessing care from traditional 11 
healers, however this was driven by one participant reporting a very high cost of $415.   12 
Indirect costs were high for all participant groups, particularly those participants being treated 13 
for TB. Job loss and other income losses were major drivers for indirect costs; accounting for 62% 14 
of cost in the participants with TB/HIV and 77% of cost for TB-only participants. Participants 15 
with TB (both TB-only and TB/HIV) lost an average of $32.53/month in income due to time spent 16 
seeking care. HIV-only participants lost substantially less income due to seeking care on average 17 
than other participant groups, at an average of $2.99 /month.  18 
About 4% of participants with TB and 3% of those with HIV their job entirely due to illness. 19 
Among those who lost their jobs due to illness, the mean and median income losses were $321.62 20 
and $207.90 respectively. The average income loss due to job loss across all participants was 21 
$17.78/month for TB-only participants, $15.40/month for TB/HIV participants, and 22 
$2.99/month for HIV-only participants.  The monetary value of time lost by guardians was 23 
particularly high for HIV-only participants. Table III shows the monthly guardian opportunity 24 
costs of time varying from $2.07 in the TB/HIV group to $4.14 in the HIV-only group.  In contrast, 25 
the cost of informal caregiving was particularly high for participants with TB (regardless of HIV 26 
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status); this cost averaged $5.81 per month for TB-only participants and $4.42 per month for 1 
TB/HIV participants.  2 
Patient time loss 3 
The time that participants lost while travelling to health facilities and accessing (and waiting for) 4 
care in the post-diagnosis period is presented in Table IV. TB/HIV participants lost the most time, 5 
averaging 91 hours per participant over the post-diagnosis period.  This was more than the 6 
combined time loss of TB-only and HIV-only participants (33.8 hours and 23.4 hours 7 
respectively).  The time lost by TB/HIV participants was driven by long hospitalisations for 11 8 
out of 116 (9.4%) participants who were hospitalised for an average of 17.7 nights over the post-9 
diagnosis period. The average time loss for TB/HIV participants not hospitalized was 50 hours 10 
over the post-diagnosis period.  Travel time, particularly for visits to the study clinic, was also 11 
substantial.  TB/HIV participants lost an average of 20 hours travelling, while TB-only and HIV-12 
only participants lost an average of 15 and 6 hours travelling, respectively.  13 
Catastrophic costs 14 
Figure I illustrates the percentages of participants facing catastrophic cost, varying thresholds 15 
from 5% to 25%. All participants had high rates of catastrophic expenditures, across thresholds. 16 
The results show that more than 60% of all participants face catastrophic costs at the 10% 17 
threshold. TB/HIV participants show the highest proportions facing catastrophic costs, with 73% 18 
of participants encountering catastrophic costs at the 5% threshold and 61% at the 25% 19 
threshold. More than 70% of HIV-only participants experienced catastrophic at 5% threshold, 20 
however this proportion dropped at higher thresholds. Considering only direct costs reduced the 21 
proportion of participants encountering catastrophic costs to 68-50% of TB/HIV participants, 46-22 
31% of TB-only participants, and 54-33% of HIV-only participants depending on threshold 23 
(Appendix Figure I).   24 
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Coping Strategies 1 
Table V shows the range of strategies adopted by participants and their households to cope with 2 
income loss and/or direct out of pocket payments incurred due to TB and/or HIV (Table V). 3 
Fifteen percent of HIV-only participants, 6% of TB/HIV participants, and 8% of TB-only 4 
participants adopted at least one coping strategy.  The most common coping strategy was loan-5 
taking, which was done by 11% of HIV-only participants, 8% of TB-only participants, and 3% of 6 
TB/HIV participants.  Interest charged on loans to the TB/HIV and HIV-only group were relatively 7 
high, at 27% and 22% of the initial value respectively.  In contrast, TB-only participants were able 8 
to source loans at zero interest from friends or family.  Government grants and charitable 9 
donations were rarely accessed across all participant groups.  Similarly, asset sales were not used 10 
by the majority of participants as a means to cope with TB and/or HIV-related costs.   11 
Discussion 12 
All participants interviewed in this study encountered high costs associated with HIV and/or TB.  13 
Over 45% of all participants experienced catastrophic costs even at thresholds as high as 25% of 14 
individual income. People with both TB and HIV on average face higher levels of post-diagnosis 15 
catastrophic costs than those with TB-only or HIV-only, especially at higher thresholds.  16 
In principle, integration has the potential to reduce the overall number of visits. We found many 17 
participants were receiving integrated care, defined as receiving multiple services within one 18 
visit. TB/HIV participants received an average of 5 ‘integrated’ TB/HIV visits in the post-diagnosis 19 
period, where both TB and HIV services were delivered on the same day.  As a result, participants 20 
received fewer TB-only visits than the TB-only group, and fewer HIV-only visits than the HIV-only 21 
group.  However, the total time loss for TB/HIV participants was still considerably higher than 22 
time loss for other participants.  Similarly, travel costs for people with TB/HIV were substantially 23 
higher than all other participants.  Given the high costs faced by those with TB/HIV, further gains 24 
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may be achieved by ensuring that ‘integrated’ visits are delivered by the same provider or within 1 
the same room, reducing waiting periods between multiple visits in a day. 2 
The gain in reduced visits observed for people with both TB and HIV may be extended by further 3 
integration, where services are provided by one provider, minimising the need for separate 4 
appointments. However, given the existing level of integration in terms of numbers of joint 5 
TB/HIV visits, it is unlikely that catastrophic cost can be averted by integration alone, and our 6 
results point to the need for timely social protection schemes such the government temporary 7 
disability grant, particularly for HIV-positive people starting TB treatment.   8 
To some degree, patients are able to cope with the costs of care, for example through taking loans 9 
with little or no interest from family and friends.  However, where costs are particularly high or 10 
where patients lack social capital, coping strategies may place patients at risk of worsened long-11 
term economic burden.  For example, access to loans in some instances can show a level of credit 12 
worthiness; particularly where loans are taken from family or friends with no interest they have 13 
been regarded in the literature as an indicator of social capital and a possible way for households 14 
to reduce the economic burden of illness (Chuma et al., 2007).  However, where loans are taken 15 
out with high interest rates or where productive assets are sold, households face the risk of long-16 
term economic hardship (Madan et al., 2015; Squire et al., 2015).  The extent of loan-taking at 17 
high interest in order to meet the costs of health care suggests that people with HIV may be at 18 
high risk of long-term economic hardship. People with HIV were also more likely to sell assets in 19 
order to pay for care; this may also translate to diminished financial status because assets may 20 
have been sold for less than their replacement values.   21 
In addition to loans and asset sale, some people received grants as well as donations to deal with 22 
costs of illness.  Currently, the South African government offers a temporary social relief of 23 
distress grant for patients who at the discretion of a doctor are deemed unfit to undertake 24 
remunerative work (Department of Social Development, 2006). However, access to these were 25 
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consistently low, with 1% of participants overall accessing government grants.  People with TB 1 
in particular had little access to the temporary disability grant, even when they were 2 
encountering catastrophic costs. This may be due to difficulty accessing the required 3 
certifications of disability within a rapid time frame.  Access to charitable donations was similarly 4 
low, with only 4 of the 454 participants interviewed accessing a donation. This notable absence 5 
of donations and grants for all participants, and TB participants in particular, shows a policy 6 
implementation gap for the most vulnerable TB patients. Further research on the reasons for this 7 
implementation gap is needed, and the South African government should thus consider 8 
alternative social protection mechanisms, such as unconditional immediate cash transfers to TB 9 
patients to close this gap (Boccia et al., 2011).  10 
Participants with HIV (both HIV-only and TB/HIV) encountered relatively high costs due to 11 
accompaniment by guardians to the study facility.  South African HIV treatment policy encourages 12 
use of a ‘treatment buddy’ to support adherence, however this is not considered a requirement 13 
for initiation onto treatment (South African Department of Health, 2010).  Nearly all HIV-only 14 
participants reported that a guardian accompanied them to their most recent PHC clinic visit.  15 
Participants with TB-only were not as frequently accompanied to the PHC clinic, and therefore 16 
had relatively lower costs.  17 
Our study supports previous findings that the primary drivers of TB patient costs are income and 18 
job loss associated with time spent care-seeking and inability to work due to illness (Muniyandi 19 
et al., 2005; Aspler et al., 2008; Ukwaja et al., 2013; Chimbindi et al., 2015).  All people with TB 20 
had high numbers of health facility visits and these were reflected in time and travel costs.  Study 21 
participants with TB also had a high rate of job loss, no matter their HIV status.  South Africa is 22 
currently scaling-up community based approaches to treatment supervision that may reduce 23 
these costs in the future.  24 
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Our study also supports previous findings that supplementary food is an important driver of TB 1 
patient costs in South Africa (Bond et al., 2008; Foster et al., 2015), raising the question of whether 2 
patients are getting appropriate education regarding nutrition and TB.  Previous studies have 3 
indicated that patients may perceive that TB and HIV drugs must be supplemented with higher 4 
food intake, often including foods outside of the normal South African diet including eggs, fruit, 5 
soft drinks, and meat (Bond et al., 2008).  Improved nutrition counselling for people with TB 6 
and/or HIV is needed to help households meet dietary needs within their normal spending 7 
capabilities. 8 
As with any patient-level costing effort, this study faced several methodological limitations.  9 
Primarily, our comparisons are made on a small sample and the participant groups we compared 10 
did not have equal numbers of participants because eligible participants were recruited 11 
consecutively, and the MERGE study had fewer participants with TB.  Methodological choices 12 
taken in this study, and the potential limitations of these are discussed in detail by Sweeney et al 13 
(2016). In practice, when conducting patient cost interviews alongside intervention studies and 14 
trials, analysts are faced with either obtaining comprehensive costs of a smaller sample or limited 15 
costs (usually OOP) from a larger sample. Due to the importance of indirect costs as highlighted 16 
by previous studies, we chose the former. We chose a recall period of 3 to 5 months; this poses 17 
some risk of recall bias, which we weighed against the potential to miss costs. Second, the patient 18 
costs questionnaire was time consuming taking up to 60 minutes. The long survey times required 19 
also pose some risk of survey fatigue for interviewees, as well as interviewers.  A number of 20 
training sessions were conducted with the interviewers and a number of recruitment guides were 21 
developed to make the recruitment process more feasible. Finally there is considerable debate in 22 
the literature surrounding the measurement of indirect costs, and the approach taken in previous 23 
studies is inconsistent (Zhang et al., 2011; Krol et al., 2013; Krol and Brouwer, 2014; Laurence et 24 
al., 2015). We chose to report income loss as our primary measure of indirect cost in order to 25 
avoid double-counting and possible bias against people with zero income, and report on time loss 26 
separately to facilitate comparison with other studies (Wingfield et al., 2014; Chimbindi et al., 27 
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2015). Further methodological research on measurement of indirect costs would facilitate future 1 
analyses of patient costs.   2 
Conclusions 3 
Given the catastrophic costs associated with TB and HIV, even in settings where TB and HIV 4 
treatment are provided for ‘free’, social and income protection policies are likely to be required 5 
to protect these patients if global targets on catastrophic cost reduction are to be met. Integration 6 
of services has potential to reduce the number of visits to the health facility, and our data shows 7 
patients are receiving this care already in South Africa. However, we also find that those with 8 
TB/HIV suffer the highest costs, and integration should be further extended to ensure that both 9 
the economic burden of ill-health and that of treatment are minimised for vulnerable households.   10 
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Table I  Demographic characteristics at time of interview, by participant group 
 
TB/HIV 
[n=116] 
TB only 
[n=40] 
HIV only 
[n=298] 
Female n (%) 63 22% 16 6% 210 73% 
Age n (%) 
18-24 10 9% 5 13% 22 7% 
25-34 43 37% 21 53% 131 44% 
35-44 48 41% 6 15% 96 32% 
≥45  13 11% 8 20% 43 14% 
South African n (%) 100 86% 32 80% 244 82% 
Black/African n (%) 111 96% 38 95% 291 98% 
Grade 8 and above n (%) 95 82% 34 85% 251 84% 
Unmarried n (%) 69 59% 24 60% 169 57% 
Employed at diagnosis n (%) 60 52% 20 50% 168 56% 
Had informal carers in post-diagnosis period n (%) 56 48% 22 55% 111 37% 
Missed work in post diagnosis period n (%) 36 31% 11 28% 37 12% 
Median CD4 count at last test (IQR) 125 275     244 216 
Median monthly income at diagnosis (2012 USD) (IQR) $150  381 $88  342 $135  312 
Median days from diagnosis to interview (IQR) 115 28 119 32 115 33 
 
 
Table II  Visits to any health care provider in the post-diagnosis period, by participant group 
Patient group TB/HIV 
[n=116] 
TB only 
[n=40] 
HIV only 
[n=298] 
Visit type TB/HIV visits TB visits HIV visits TB/HIV visits TB visits HIV visits TB/HIV visits TB visits HIV visits 
Study clinic visits, mean (SD) 5.0 (4.6) 10.9 (14.2) 2.2 (4.6) 0.8 (.6) 14.5 (14.6) 0.1 (.2) 0 0 4.4 (2.0) 
Visits to **other providers, mean (SD) 
 
0.3 (0.7) 0.2 (0.7) 
 
0.6 (2.6) 0.1 (0.2) 
 
0 0.2 (0.7) 
Subtotal, all providers, mean 5.0 11.2 2.2 0.8 15.1 0.1 0 0 4.6 
Total Visits, all visit types, all providers 18.4 16.0 5.1 
SD standard deviation 
**Other public clinic, pharmacy, general practitioner, hospital-outpatient, hospital-inpatient and traditional healers 
Table III  Monthly direct and indirect costs (USD 2013), by participant group 
 
TB/HIV 
(n=116) 
TB only 
(n=40) 
HIV only 
(n=298) 
  mean (SD) Mean (SD) mean (SD) 
Direct costs             
  Patient medical             
    Study clinic 0.00 0.00 0.00 0.00 0.00 0.00   
Any other facility 1.71 10.23 0.07 0.42 0.87 4.12 
  Patient travel               
Study clinic 4.12 8.91 1.69 3.31 1.25 3.07 
    Any other facility 0.63 2.89 0.05 0.20 0.24 1.37 
  Guardian travel                
Study clinic 0.43 2.37 0.00 0.00 0.27 2.78 
    Any other facility 0.51 3.11 0.00 0.00 0.17 1.52 
  Food               
Hospital 0.26 1.31 0.00 0.00 0.04 0.47 
    Special foods 13.14 17.33 8.06 11.05 9.76 14.91 
  Loan interest 0.93 9.78 0.00 0.00 5.68 89.11 
Total direct costs 21.72 (29%1) 9.86 (14%1) 18.28 (45%1) 
Indirect costs             
  Patient income loss             
  
 
Job loss income loss    15.40 126.17 17.78 76.69 2.99 24.30 
  
 
Care-seeking income loss 30.45 105.56 34.60 98.99 13.81 59.03 
  Opportunity costs of time              
Guardian               
Study clinic 1.13 2.37 0.23 0.00 3.92 2.78 
    Any other facility 0.94 6.16 0.04 0.24 0.22 1.24 
  Carer 4.42 11.35 5.81 13.52 1.19 5.77 
Total indirect costs 52.34 (71%1) 58.47 (86%1) 22.13 (55%1) 
Grand total  74.07 68.33 40.41 
SD standard deviation 
1 percentage of the overall total 
 
Table IV   Total time loss in post-diagnosis period (hours), by participant group 
    TB/HIV 
(n=116) 
TB only 
(n=40) 
HIV only 
(n=298) 
    mean (SD) Mean (SD) mean (SD) 
Study clinic Consulting 28.2 27.7 17.5 17.3 13.9 11.7 
Travel 20.7 20.7 15.4 17.3 5.6 6.4 
 Subtotal 48.9 (54%) 32.9 (97%) 19.6 (83%) 
Other clinic Consulting 0 0.2 0.3 1.0 0.1 0.5 
Travel 0.1 0.5 0.5 1.4 0.2 1.3 
 Subtotal 0.1 (0%) 0.8 (2%) 0.2 (1%) 
Pharmacy Consulting 0 0.2 0 0.1 0 0.4 
Travel 0 0.3 0 0.1 0.1 0.4 
 Subtotal 0.1 (0%) 0 (0%) 0.1 (0%) 
General 
practitioner 
Consulting 0.1 0.7 0 0.3 0.3 1.8 
Travel 0.2 1.2 0 0 0.2 0.8 
 Subtotal 0.3 (0%) 0 (0%) 0.4 (2%) 
Hospital-
inpatient 
Consulting 40.3 146.8 0 0 2.9 25.5 
Travel 0.3 1.0 0 0 0.1 0.7 
 Subtotal 40.6 (45%) 0 (0%) 3.0 (13%) 
Hospital-
outpatient 
Consulting 0.2 1.0 0 0 0 0 
Travel 0.5 3.2 0 0 0 0 
 Subtotal 0.7 (1%) 0 (0%) 0 (0%) 
Traditional 
healer 
Consulting 0 0.3 0 0 0 0.2 
Travel 0.1 0.8 0 0 0.1 0.9 
 Subtotal 0.1 (0%) 0 (0%) 0.2 (1%) 
Grand total 90.8 33.8 23.4 
SD standard deviation 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure I  Catastrophic costs due to illness, by participant group 
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Table V  Coping strategies, by participant group 
 TB/HIV 
(n = 116) 
TB only 
(n = 40) 
HIV only 
(n = 298) 
Grants and donations    
Patients receiving government grants n (%) 1 (1%) 0 5 (2%) 
Patients receiving charitable donations n (%) 0 (%) 0 4 (1%) 
Asset Sale    
Patients selling assets n (%) 3 (3%) 0 7 (2%) 
Mean value of assets sold (USD) $11.54 - $9.15 
Loans    
Patients taking loans n (%) 4 (3%) 3 (8%) 34 (11%) 
Mean interest on loans (% of initial withdrawal) 27% 0% 22% 
Total adopting any coping strategy 7 (6%) 3 (8%) 46 (15%) 
Total adopting multiple strategies 1 (1%) 0 4 (1%) 
 
 
Appendix Table I  Detailed health service use at all facility types, by participant 
group 
 
Number of participants 
Mean number of visits in post 
diagnosis period 
Participant group TB/HIV 
(n = 116) 
TB only 
(n = 40) 
HIV only 
(n = 298) 
TB/HIV 
(n = 116) 
TB only 
(n = 40) 
HIV only 
(n = 298) 
Study Clinic       
TB/HIV visits 91 27 0 6.4 1.1  
TB visits 95 39 0 13.3 14.9  
HIV visits 52 2 298 4.4 1.0 4.6 
Other Clinic       
TB visits 6 5 0 1.3 4.4  
HIV visits 2 2 7 1.5 1.0 1.6 
Pharmacy       
TB visits 2 0 0 1.5   
HIV visits 2 0 10 1.5  1.2 
General 
Practitioner 
      
TB visits 4 1 0 1.8 1.0  
HIV visits 3 0 20 3.3  1.6 
Hospital 
(inpatient) 
      
TB visits 10 0 0 1.2   
HIV visits 3 0 2 1.0  1.0 
Hospital 
(outpatient) 
      
TB visits 3 0 0 2.0   
HIV visits 5 0 0 1.2   
Traditional Healer       
TB visits 1 0 0 1.0   
HIV visits 0 0 9   1.7 
 
Appendix Table II – Detailed costs for all facility types, by participant group 
    TB/HIV 
(n=116) 
TB only 
(n=40) 
HIV only 
(n=298) 
    mean (SD) Mean (SD) mean (SD) 
D
ir
e
ct
 c
o
st
s 
Medical Study clinic 0.00 0.00 0.00 0.00 0.00 0.00 
Other clinic 0.00 0.00 0.00 0.00 0.00 0.00 
Pharmacy 0.00 0.01 0.07 0.42 0.00 0.00 
General practitioner 0.30 2.72 0.00 0.00 0.82 4.13 
Hospital-outpatient 0.11 0.70 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.32 2.28 0.00 0.00 0.01 0.14 
Traditional healer 1.00 9.67 0.00 0.00 0.05 0.44 
Travel Patient Study clinic 4.12 8.91 1.69 3.31 1.25 3.07 
Other clinic 0.02 0.12 0.05 0.20 0.02 0.15 
Pharmacy 0.00 0.00 0.00 0.00 0.04 0.35 
General 
practitioner 
0.30 2.70 0.00 0.00 0.13 1.10 
Hospital-outpatient 0.21 0.93 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.06 0.43 0.00 0.00 0.03 0.60 
Traditional healer 0.04 0.48 0.00 0.00 0.01 0.13 
Guardian Study clinic 0.43 2.37 0.00 0.00 0.27 2.78 
Other clinic 0.00 0.00 0.00 0.00 0.01 0.08 
Pharmacy 0.00 0.00 0.00 0.00 0.01 0.18 
General 
practitioner 
0.25 2.65 0.00 0.00 0.05 0.81 
Hospital-outpatient 0.12 0.83 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.14 1.45 0.00 0.00 0.10 1.28 
Traditional healer 0.00 0.00 0.00 0.00 0.01 0.09 
Food Hospital 0.26 1.31 0.00 0.00 0.04 0.47 
Special foods 13.14 17.33 8.06 11.05 9.76 14.91 
Loan interest 0.93 9.78 0.00 0.00 5.68 89.11 
Total direct 21.72 29%1 9.86 14% 18.28 45%1 
In
d
ir
e
ct
 C
o
st
s 
Patient 
Income 
Loss 
Job loss income loss    15.40 126.17 17.78 76.69 2.99 24.30 
Care-seeking income loss 30.45 105.56 34.60 98.99 13.81 59.03 
Opportunity 
Costs of 
Time 
Guardian Study clinic 1.13 4.58 0.23 1.00 3.92 3.35 
Other clinic 0.00 0.00 0.03 0.17 0.03 0.36 
Pharmacy 0.00 0.00 0.01 0.06 0.00 0.04 
General 
practitioner 
0.03 0.32 0.00 0.00 0.04 0.41 
Hospital-outpatient 0.05 0.65 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.88 6.19 0.00 0.00 0.13 1.11 
Traditional healer 0.00 0.00 0.00 0.00 0.01 0.16 
Carer 4.42 11.35 5.81 13.52 1.19 5.77 
Total indirect 52.34 71%1 58.47 86% 22.13 55%1 
Grand total  74.07   68.33   40.41   
1 percentage of the overall total 
 
Appendix Figure I  Catastrophic costs due to illness, by patient group (direct costs only) 
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